ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Nvidia Develops New Location-Verification Technology for AI Chips 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach this milestone. The company’s extraordinary rise is fueled largely by explosive global demand for weight-loss and diabetes treatments, a sector that has rapidly transformed into one of healthcare’s most lucrative markets.
Lilly’s stock has surged more than 35% this year thanks to the success of its blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In a remarkable shift, sales of these medicines have even surpassed Merck’s Keytruda, making tirzepatide the world’s best-selling drug. Mounjaro and Zepbound have also helped Lilly overtake longtime rival Novo Nordisk, which initially dominated the obesity-drug landscape. Novo’s Wegovy faced early supply shortages after its 2021 launch, giving Lilly crucial momentum. Stronger clinical results and faster manufacturing expansion further accelerated Lilly’s lead.
Shares briefly hit an all-time high near $1,051, and the stock now trades at a premium valuation—about 50 times expected earnings—reflecting investor confidence in long-term demand for GLP-1 treatments. Since Zepbound’s late-2023 debut, Lilly’s market performance has far outpaced the broader S&P 500, climbing more than 75%.
In the latest quarter, Lilly reported over $10 billion in combined obesity and diabetes drug revenue, representing more than half of its total $17.6 billion sales. Analysts say the company’s pipeline, pricing agreements with the U.S. government, and major domestic manufacturing investments position Lilly for continued dominance, even if near-term revenue faces pressure.
Wall Street projects the global weight-loss drug market could reach $150 billion by 2030, with Lilly poised to control a large share—especially as investors anticipate approval of its promising oral drug, orforglipron, next year.
Still, analysts caution that sustaining growth will require navigating price pressure, scaling production, and maintaining a strong pipeline. Even so, many now view Lilly as a potential alternative to tech-sector giants, especially as some AI stocks experience volatility.
